Icon, a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries, has announced a new service agreement with Pfizer.
The agreement, which covers the provision of clinical development services, will see Icon working with Pfizer to advance the development of new treatments for patients around the world. The partnership will focus on clinical trial design and execution, data management, and regulatory support.
According to Dr. Steve Cutler, CEO of Icon, the agreement reflects the company`s commitment to delivering high-quality services to its clients. “We are delighted to be partnering with Pfizer on this important initiative,” he said. “Our team of experts is dedicated to helping our clients bring new treatments to market as quickly and efficiently as possible, and we look forward to working closely with Pfizer on this exciting project.”
For Pfizer, the agreement represents a significant milestone in its efforts to expand its pipeline of innovative therapies. “We are very pleased to be working with Icon on this strategic initiative,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer. “We believe that their expertise and experience in clinical trial design and execution will be instrumental in helping us achieve our goals.”
As part of the new agreement, Icon and Pfizer will collaborate on a range of clinical development programs across multiple therapeutic areas. This will involve the integration of data and expertise from both companies, as well as the use of cutting-edge technologies and methodologies to optimize trial design and execution.
Overall, the new service agreement between Icon and Pfizer is a positive development for the pharmaceutical industry. By combining their respective strengths and expertise, these companies have the potential to accelerate the development of new treatments and improve health outcomes for patients around the world.